TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Genevant Sciences and Tome Biosciences Are Partnering to Develop a Gene Editing Therapeutic for a Rare Liver Disorder

Wednesday, January 17, 2024

Genevant Sciences, a leading company in nucleic acid delivery with a strong lipid nanoparticle (LNP) patent portfolio, has recently announced a collaboration and nonexclusive license agreement with Tome Biosciences. This partnership aims to combine Genevant's proprietary LNP technology with Tome's programmable genomic integration (PGI) technology to develop an in vivo gene editing treatment for an undisclosed rare monogenic liver disorder.

According to Pete Lutwyche, Ph.D., President and CEO of Genevant Sciences, the success of next-generation gene editing approaches, like Tome's, relies on effective delivery mechanisms, emphasizing the importance of Genevant's LNP technology. Lutwyche stated, "We are pleased to be working with Tome to bring its innovative gene editing technology to patients."

Rahul Kakkar, CEO of Tome, expressed anticipation for the collaboration, highlighting Genevant's leadership in the LNP space. The terms of the agreement and a completed evaluation agreement outline a total deal value of $114.3 million for Genevant. Furthermore, Genevant will receive tiered royalties based on future product sales resulting from this collaborative effort.



patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO SummitThe Healthcare Patient Experience & Engagement SummitHealthcare Innovation & Transformation Summit